 GeoVax Labs Inc NASDAQ: GOVX initiated vaccine dosing in the Phase 2 portion of its Phase 12 trial of COH04S1 COVID-19 vaccine to target both the spike S and nucleocapsid N proteins. The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy adult individuals aged 18 to 55 who had not been previously infected with SARS-CoV-2. 